ReviewSports medicine (Auckland, N.Z.)2005
Erythropoietin abuse and erythropoietin gene doping: detection strategies in the genomic era.
Review in Sports medicine (Auckland, N.Z.), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 61 citations in OpenAlex.
- [Gene doping: current test methods and analytical challenges].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026Review
- Recombinant Human Erythropoietin Effects on Well-Trained Athletes' Endurance Performance: A Systematic Review.Sports (Basel, Switzerland) · 2025Review
- Peptides from Natural or Rationally Designed Sources Can Be Used in Overweight, Obesity, and Type 2 Diabetes Therapies.Molecules (Basel, Switzerland) · 2020Review
- Gene doping in sport - perspectives and risks.Biology of sport · 2014Article
- From gene engineering to gene modulation and manipulation: can we prevent or detect gene doping in sports?Sports medicine (Auckland, N.Z.) · 2013Review
- Hormones as doping in sports.Endocrine · 2013Review
- Erythropoietin use and abuse.Indian journal of endocrinology and metabolism · 2012Article
- Genetic doping and health damages.Iranian journal of public health · 2011Article
- Oxidative stress: Biomarkers and novel therapeutic pathways.Experimental gerontology · 2010Review
- Athlete atypicity on the edge of human achievement: performances stagnate after the last peak, in 1988.PloS one · 2010Article
- Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology.TheScientificWorldJournal · 2009Review
- Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies.Progress in neurobiology · 2008Review
- Erythropoiesis-stimulating agents and other methods to enhance oxygen transport.British journal of pharmacology · 2008Review
- Erythropoietin and oxidative stress.Current neurovascular research · 2008Review
- Raves and risks for erythropoietin.Cytokine & growth factor reviews · 2008Review
- Review
- New strategies for Alzheimer's disease and cognitive impairment.Oxidative medicine and cellular longevityReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The administration of recombinant human erythropoietin (rhEPO) increases the maximum oxygen consumption capacity, and is therefore abused as a doping method in endurance sports. The detection of erythropoietin (EPO) abuse is based on direct pharmacological and indirect haematological approaches, both of which have several limitations. In addition, current detection methods cannot cope with the emerging doping strategies of EPO mimicry, analogues and gene doping, and thus novel detection strategies are urgently needed. Direct detection methods for EPO misuse can be either pharmacological approaches that identify exogenous substances based on their physicochemical properties, or molecular methods that recognise EPO transgenes or gene transfer vectors. Since direct detection with molecular methods requires invasive procedures, it is not appropriate for routine screening of large numbers of athletes. In contrast, novel indirect methods based on haematological and/or molecular profiling could be better suited as screening tools, and athletes who are suspect of doping would then be submitted to direct pharmacological and molecular tests. This article reviews the current state of the EPO doping field, discusses available detection methods and their shortcomings, outlines emerging pharmaceutical and genetic technologies in EPO misuse, and proposes potential directions for the development of novel detection strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.